BRAF is a therapeutic target in aggressive thyroid carcinoma

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1623-1629

  Salvatore, Giuliana ^a   De Falco, Valentina ^a   Salerno, Paolo ^a   Nappi, Tito Claudio ^a   Pepe, Stefano ^a   Troncone, Giancarlo ^a   Carlomagno, Francesca ^a   Melillo, Rosa Marina ^a   Wilhelm, Scott M ^b   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN; SORAFENIB;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; GENE MUTATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RNA INTERFERENCE; THYROID CARCINOMA; THYROID CELL; THYROID PAPILLARY CARCINOMA; XENOGRAFT;

ANIMALS; BENZENESULFONATES; CARCINOMA; CARCINOMA, PAPILLARY; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645069923     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2378     Document Type: Article

References (41)

1. DeLellis RA, Williams ED. Thyroid and parathyroid tumors. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Tumours of endocrine organs. World Health Organization classification of tumors. International Agency for Research on Cancer (Lyons, France): IARC Press: 2004. p. 51-6.
2. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
3. Ordonez N, Baloch Z, Matias-Guiu X, et al. Undiffer-entiated (anaplastic) carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Tumours of endocrine organs, World Health Organization classification of tumors. International Agency for Research on Cancer (Lyons, France): IARC Press: 2004. p. 77-80.
4. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64-9.
5. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78-83.
6. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003;4:95-8.
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BR AF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
8. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
9. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesisof PTC Oncogene 2003;22:4578-80.
10. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
11. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004;89:1365-8.
12. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
13. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
14. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9. Epub 2005 September 20.
15. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62.
16. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
17. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101.
18. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-81.
19. Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Jr., Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465-73.
20. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238-45.
21. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
22. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003;4:757-63.
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
24. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
25. Pang XP, Hershman JM, Chung M, et al. Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 1989;125:1783-8.
26. Fiore L, Pollina LE, Fontanini G, et al. Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 1997;82:4094-100.
27. Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of Taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996;81:3650-3.
28. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-84.
29. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369-71.
30. Curcio F, Ambesi-Impiombato FS, Perrella G, Coon HG. Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc Natl Acad Sci U S A 1994;91:9004-8.
31. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
32. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
33. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
34. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
35. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90.
36. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599E B-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21.
37. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8.
38. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-8.
39. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
40. Frantz S. Drug discovery: playing dirty. Nature 2005;437:942-3.
41. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004;23:6292-8.